Roche's $8.3 billion bid for InterMune
(ITMN) led the biotech sector up on Monday. In the wake of the news, UBS highlighted Achillion as another potential merger and acquisition target.
"While we had viewed InterMune as a top take-out candidate in biotech, we also note our Buy rating on Achillion Pharmaceuticals shares also reflects M&A potential," the firm wrote, according to Barron's.
Must Read: Warren Buffett's 25 Favorite Stocks
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.